国药集团一致药业股份有限公司 2025年6月30日 负债和所有者权益总计 法定代表人 主管会计工作负责人: 会计机构负责人: 资产负债表(合并) | | 八月八日六 六月六 | 单位:人民币元 | | --- | --- | --- | | | 期末余额 | 期初余额 | | 流动资产: | | | | 货币资金 | 6,797,307,998.31 | 7,408,539,662.57 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 385,257,647.22 | 657,474,352.88 | | 应收账款 | 23,747,157,113.52 | 19,376,751,928.72 | | 应收款项融资 | 730,289,148.84 | 1,071,756,277.75 | | 预付款项 | 344,838,163.22 | 692,054,330.53 | | 应收保费 | | | | 应收分保账款 | | | | 应收分保合同准备金 | | | | 其他应收款 | 611,100,198.19 | 7 ...

证券代码：000028、200028 证券简称：国药一致、一致 B 公告编号：2025-35 二、董事会会议审议情况 1. 审议通过了《国药一致 2025 年半年度报告及摘要》 表决结果：9 票同意，0 票反对，0 票弃权。 本议案经第十届董事会风险内控与审计委员会 2025 年第三次会议审 议通过。具体内容详见当日公告及巨潮资讯网。 2. 审议通过了《关于对国药集团财务有限公司的风险持续评估报告》 国药集团一致药业股份有限公司 第十届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 国药集团一致药业股份有限公司（以下简称"公司"）第十届董事会 第五次会议于2025年8月18日以电子邮件方式发出通知和文件材料，会议于 2025年8月28日以现场会议结合视频会议方式在广州召开。应参加会议董事 9名，实际出席会议董事9名。公司高级管理人员列席本次会议。董事长吴 壹建先生主持本次董事会。会议的召集召开程序符合《公司法》《公司章 程》的有关规定。 2025 年 8 月 30 日 表决结果：关联董事吴壹建、罗娴、章伟、贾洪 ...

国药一致总经理工作细则 1 国药集团一致药业股份有限公司 总经理工作细则 第 一 章 总 则 第一条 为完善国药集团一致药业股份有限公司（以下简称"公司"）的法人 治理结构，明确公司经营管理层的工作权限，规范公司经营管理层的工作行为，保 证其依法履行职责，依照《中华人民共和国公司法》《上市公司治理准则》等法律 法规和《国药集团一致药业股份有限公司章程》（以下简称"公司章程"）的规定， 并结合公司的实际情况，特制定本细则。 第二条 公司总经理主持公司日常生产经营和管理工作，负责组织和实施董事 会决议，对董事会负责。 第 二 章 总 经 理 职 权 第三条 总经理对董事会负责，行使下列职权： （一）组织执行董事会的决议，主持公司的生产经营管理工作并向董事会报告 工作； （二）主持拟订公司中长期发展规划、重大投资项目及年度生产经营计划和投 资方案； （三）主持拟订公司年度财务预算、决算方案；拟订公司税后利润分配方案、 弥补亏损方案和公司资产用于抵押融资的方案； （四）主持拟订公司增加或减少注册资本和发行公司债券的建议方案； （七）主持拟订公司基本管理制度，制定公司具体规章； （八）提请董事会聘任或解聘公司副总经理、 ...

Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of the year, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved operating revenue of 36.797 billion yuan, a year-on-year decrease of 2.62% [1] - The net profit attributable to shareholders was 666 million yuan, reflecting a year-on-year decline of 10.43% [1] - The basic earnings per share were reported at 1.2 yuan [1]

国药集团一致药业股份有限公司 2025 年半年度报告全文 国药集团一致药业股份有限公司 2025 年半年度报告 2025 年 8 月 1 国药集团一致药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人吴壹建、主管会计工作负责人谷国林及会计机构负责人(会计 主管人员)王雪飞声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | 1 | | --- | --- | --- | | | 1 | | | 1 | | P | | 第一节 | 重要提示、目录和释义 | | 2 | | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | | 6 | | 第三节 | 管理层讨论与分析 | | 9 | | 第四节 | 公司治理、环境和社会 | | 27 | | 第五节 | 重要事项 | | 28 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.71% on August 27, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Saily Medical (603716) closed at 33.15, down 8.93% with a trading volume of 484,700 shares and a transaction value of 1.671 billion [1] - Other notable declines included HeLiang China (603122) down 5.15%, YaoYigou (300937) down 5.10%, and Guofa Shares (600538) down 4.98% [1] - The overall net outflow of main funds from the pharmaceutical commercial sector was 543 million, while retail investors saw a net inflow of 361 million [1] Fund Flow Analysis - Jiuzhoutong (600998) had a main fund net inflow of 11.8 million, accounting for 18.23% of its total [2] - Dacilin (603233) saw a main fund net inflow of 29.97 million, representing 15.70% [2] - The overall trend indicates a mixed sentiment with main funds withdrawing while retail investors are actively buying [2]

Market Overview - The Shanghai Composite Index closed at 3888.00 points, with a slight increase of 0.11% and total trading volume of 169.94 billion yuan [1] - A total of 26 A-shares have surpassed their annual moving average, indicating positive market sentiment [1] Notable Stocks - Creative Information (300366) showed the highest deviation rate of 4.01%, with a daily increase of 4.72% and a turnover rate of 13.12% [1] - TCL Smart Home (002668) followed with a 3.37% deviation rate, increasing by 5.49% today [1] - Weiming Environmental (603568) had a deviation rate of 2.57%, with a daily increase of 3.46% [1] Stocks with Smaller Deviations - China National Pharmaceutical (600938), Zhongju High-tech (600872), and China Oil (000028) all had minor deviation rates, just above their annual lines, with increases of 0.31%, 1.11%, and 0.57% respectively [2]

Market Overview - The pharmaceutical commercial sector increased by 0.05% on August 20, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Stock Performance - Yifeng Pharmacy (603939) closed at 24.27, up 0.87% with a trading volume of 58,700 shares and a turnover of 141 million yuan [1] - Other notable performers include: - Liuyuan Group (603368) at 18.64, up 0.76% [1] - China National Pharmaceutical Group (600511) at 30.01, up 0.60% [1] - Shanghai Pharmaceuticals (601607) at 19.02, up 0.58% [1] - Nanjing Pharmaceutical (600713) at 5.30, up 0.57% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 377 million yuan from institutional investors, while retail investors saw a net inflow of 367 million yuan [2] - Notable capital flows include: - Yifeng Pharmacy had a net outflow of 9.79 million yuan from institutional investors [3] - Heavy Drug Holdings (000950) saw a net inflow of 7.45 million yuan from institutional investors [3] - Drug Easy Purchase (300937) had a net inflow of 3.82 million yuan from institutional investors [3]

数据显示，8月15日国药一致主力资金净流出1837.68万元，近五日累计净流出1337.77万元。 风险提示：以上信息仅供参考，不构成任何投资建议。 该公司属于医药商业板块，是中国医药集团旗下拥有"分销+零售+工业投资"完整产业链的综合性医药上 市公司。其业务覆盖全国医药零售网络及两广地区分销网络，为全国医疗机构和零售终端提供医药供应 链服务。 根据公司披露的业绩快报，2025年上半年实现营业总收入367.97亿元，同比下降2.62%；归母净利润 6.66亿元，同比下降10.43%。值得注意的是，零售板块表现突出，实现净利润0.17亿元，同比增长 215.81%，主要得益于业务结构优化和经营质量提升。 国药一致最新股价报25.82元，较前一交易日上涨0.23元。盘中最高触及25.87元，最低下探25.58元，成 交金额达1.11亿元。 ...

Core Viewpoint - The company reported a decline in both total revenue and net profit for the first half of 2025 compared to the previous year [2] Financial Performance - The total operating revenue for the first half of 2025 was 36,796.60 million yuan, representing a year-on-year decrease of 2.62% [2] - The net profit attributable to shareholders of the listed company was 665.91 million yuan, showing a year-on-year decline of 10.43% [2]